Ovarian Cancer Clinical Trial

Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression

Summary

An open-label, Phase 1/2a study of HPN536 as monotherapy to assess the safety, tolerability and PK in patients with advanced cancers associated with mesothelin expression.

View Eligibility Criteria

Eligibility Criteria

One of the following progressive advanced or metastatic cancers:

Epithelial ovarian, fallopian tube, or primary peritoneal cancer that is platinum refractory or platinum resistant
Pancreatic adenocarcinoma that is locally advanced, and now with progressive disease on or after front-line treatment
Malignant mesothelioma with epithelioid histology, pleural or peritoneal
For Part 2 only - Measurable disease according to RECIST v1.1 for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, pancreatic adenocarcinoma, and peritoneal mesothelioma, and mRECIST v1.1 for patients with pleural mesothelioma
Available archival tissue sample, or fresh biopsy tissue sample must be obtained prior to enrollment. For Part 2 only- a fresh biopsy tissue sample is required.

Adequate bone marrow function, including:

Absolute neutrophil count (ANC) ≥1500/mm3 or ≥1.5 x 109/L
Platelets ≥100,000/mm3 or ≥100 x 109/L
Hemoglobin (Hgb) ≥9 g/dL
Adequate renal function, including estimated creatinine clearance ≥30 mL/min

Adequate liver function, including:

Total serum bilirubin ≤1.5 x upper limit of normal (ULN) unless the patient has documented Gilbert syndrome in which case the maximum total serum bilirubin should be <5 mgdL
Aspartate and alanine transaminase (AST and ALT) ≤2.5 x ULN or AST/ALT ≤5 x ULN for patients with liver metastases
Serum albumin ≥30 mg/mL

Key Exclusion Criteria:

Brain metastases unless previously treated. Patients with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks prior to study entry, and have no evidence of new or enlarging brain metastases
Evidence of retroperitoneal fibrosis, mesothelial surface (pleura, pericardium, peritoneum) thickening of ≥4 mm; significant or increasing pleural/pericardial effusions, ascites or pericarditis at baseline deemed unrelated to the underlying malignancy basedon computed tomography (CT), magnetic resonance imaging (MRI), or echocardiogram (ECHO); or prior history of pleurodesis, retroperitoneal fibrosis or mediastinal fibrosis.
Previous Grade 3/4 infusion or hypersensitivity reaction (not immunotoxicity) to treatment with another monoclonal antibody.
For patients with tumor types other than pleural mesothelioma: Ascites requiring >1 paracentesis for therapeutic purposes (i.e., not for diagnosis) within 1 month prior to Cycle 1 Day 1.

Study is for people with:

Ovarian Cancer

Phase:

Phase 1

Estimated Enrollment:

200

Study ID:

NCT03872206

Recruitment Status:

Active, not recruiting

Sponsor:

Harpoon Therapeutics

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 16 Locations for this study

See Locations Near You

Mayo Clinic Arizona
Phoenix Arizona, 85054, United States
University of Southern California
Los Angeles California, 90007, United States
University of California Los Angeles
Los Angeles California, 90095, United States
Mayo Clinic Florida
Jacksonville Florida, 32224, United States
University of Chicago
Chicago Illinois, 60637, United States
Massachusetts General Hospital
Boston Massachusetts, 02114, United States
Mayo Clinic Rochester
Rochester Minnesota, 55905, United States
Washington University School of Medicine in St. Louis
Saint Louis Missouri, 63110, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10017, United States
Cleveland Clinic Taussig Cancer Institute
Cleveland Ohio, 44195, United States
Stephenson Cancer Center
Oklahoma City Oklahoma, 73104, United States
Thomas Jefferson University
Philadelphia Pennsylvania, 19107, United States
Sarah Cannon Research Institute
Nashville Tennessee, 37203, United States
Mary Crowley Cancer Research
Dallas Texas, 75230, United States
University of Virginia Cancer Center
Charlottesville Virginia, 22903, United States
University of Washington Medical Center
Seattle Washington, 98195, United States

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 1

Estimated Enrollment:

200

Study ID:

NCT03872206

Recruitment Status:

Active, not recruiting

Sponsor:


Harpoon Therapeutics

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.